Chief Executive Officers
Chief Scientific Officers
VPs, Directors, Managers of Business Development
VPs, Directors & Managers of Licensing
Group Leaders
Medical Directors
Professors
Principal Investigators
Research Fellows
Research Scientists
Scientists
Consultants
Regulators
Venture Capitalists
About the Conference
The World Cancer Immunotherapy Conference is bringing together leading scientists and C-Level executives from across the globe to present research, case studies and viewpoints on various topics integral to a better understanding of the challenges and opportunities facing developers of therapeutic cancer vaccines.
With the recent commercialization of Provenge, an approval path has now been mapped out, albeit with major challenges in terms of uptake and reimbursement. Moreover, with other novel vaccines nearing approval, now is the time to revisit the successes and failures of this development program as well as the challenges that still lie ahead.
Key Questions Answered
- What types of improvements need to be made to clinical trial designs and endpoints in order to maximize chances for success?
- How is the biomarker and personalized medicine revolution going to aid the development of cancer vaccines?
- What are the challenges facing developers of autologous vs allogenic cancer vaccines?
- What are the best delivery routes for cancer vaccines?
- What are the current reimbursement challenges facing developers?
Topics and Themes
Speakers and panelists at this conference will discuss the following:
- Cancer vaccine clinical trial design
- FDA guidance for cancer vaccine developers and regulatory challenges
- Biomarkers as an aid to clinical development of cancer vaccines
- Optimal disease settings for cancer vaccine intervention
- Cancer vaccines in combination therapies